Rescued cat sparks warning over 'extreme breeding'
"His story is also a stark reminder of the dangers of breeding for appearance over welfare."We're so relieved Alfred is now with us where he can be properly cared for," Mr Hughes added.
'Sweetest boy'
Alfred is at risk of several health challenges due to his genetics, including a lack of whiskers, hairlessness and short legs that can cause pain and limit his mobility, the centre detailed. He also has entropion, a painful condition in which the eyelid turns inward, causing fur to rub against and irritate the eye. "We all adore Alfred," said Mr Hughes. "He is the sweetest boy, and his story has touched everyone at the centre."He is incredibly affectionate. He follows the team around and just wants to be close to people."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
29 minutes ago
- The Independent
What to know about bovine tuberculosis as disease hits Diddly Squat Farm
Jeremy Clarkson 's Diddly Squat Farm in the Cotswolds has been hit by an outbreak of bovine tuberculosis (bTB) among its cattle. Clarkson announced on 31 July that the farm team was "devastated" after a pregnant cow contracted the disease, with tests for the beloved bull Endgame proving inconclusive. Following failed biannual tests for some cattle, the farm is now under restrictions, preventing the buying or selling of cows, though the Diddly Squat shop remains unaffected. The infected pregnant cow, carrying twins, will be culled, a decision Clarkson described as "awful" and emotionally distressing for the farm. Bovine TB is a chronic respiratory disease that primarily affects cattle, often leading to culling to control its spread, though human transmission is very rare. What is bovine tuberculosis? Everything you need to know about the disease affecting Jeremy Clarkson's Diddly Squat farm
The Independent
29 minutes ago
- The Independent
Alzheimer's ‘wonder drug' slows progression of disease by four years - and could even reverse it
An Alzheimer's 'wonder drug' can delay the progression of the disease by four years, according to a new study. Researchers found that patients who were given the drug lecanemab in the earliest days of their disease reported an improvement, or no decline at all, in cognitive function. The trial of 478 patients who stayed on the drug for four years saw their dementia score rise by an average of 1.75 over the whole period - a score significantly lower than the average rise of one or two points over one year. Almost one million people in the UK suffer from dementia, with Alzheimer's the most common form of the disease. Urgent demand for new treatments is increasing as the number is expected to rise to 1.4 million by 2040. The new data presented at the Alzheimer's Association International Conference in Toronto suggested the drug was most promising for those with low levels of tau, the protein that grows as Alzheimer's progresses. In a subgroup of patients with low levels of tau, promising results showed 69 per cent of the group had no decline at all over four years, and 56 per cent saw an improvement in their cognitive scores. Speaking to The Telegraph, Professor Christopher Van Dyck, the director of the Alzheimer's Research unit at the Yale school of medicine and the study leader, said: 'The thing I really focus on is the time saved. You will get worse over time, but it will take longer to get there.' Lecanemab was approved for use in the UK last year after trials showed its effectiveness in slowing the progression of the disease. It is a disease-modifying drug, which means that it was developed to tackle the causes of Alzheimer's disease rather than only relieving the symptoms. It works by targeting the protein amyloid, which is thought to build up in the brain and become toxic to brain cells, causing Alzheimer's symptoms. Other similar drugs, like donanemab, have also been shown to slow the rate at which memory and thinking get worse by more than 20 per cent. Both drugs are approved by the Medicines and Healthcare products Regulatory Agency (MHRA) but were rejected for use by the NHS because the benefits were deemed to be 'too small' to justify the cost. Dr Sheona Scales, the director of research at Alzheimer's Research UK, told The Telegraph: 'These latest findings offer renewed hope that Alzheimer's treatments can meaningfully change the course of the disease, not just slow decline in the short term. 'New long-term data show that the benefits of donanemab may continue even after treatment ends, and people on lecanemab for up to four years maintained cognitive gains, with some even improving. Among those treated early with lecanemab and with low levels of tau, over half showed no decline after four years. 'This is the first wave of disease-modifying treatments for Alzheimer's and, while the progress is encouraging, there are still many pieces of the puzzle we don't yet have.'
BBC News
30 minutes ago
- BBC News
Jersey fundraiser finishes challenge in memory of her mum
A Jersey fundraiser finished her challenge to run 5k (3.2miles) every day through the month of July in memory of her Daly's mum, Nicola, died from malignant melanoma five years ago, which is a type of skin cancer that can spread to other areas of the 27-year-old has raised more than £6,400 for MacMillan Jersey, which supported her mum during her cancer Daly was joined by friends and family throughout her runs and they gathered at the Waterfront Gardens to cheer her on as she finished the challenge. Ms Daly has been sharing her challenge on social media to also make more people aware of the dangers of skin said: "People think it's just skin cancer and you can cut it out and it's gone but that wasn't the case with my mum and it's not the case for a lot of people."Ms Daly added: "The most emotional thing was I just wish she was here," adding: "She would've been there every step of the way and I know she is there but I can't see her or talk to her".It was an emotional finish to the fundraising as Ms Daly shed some tears as she crossed the finish line, and also said: "I've never done anything like this before". Megan Winton was one of the runners who joined Ms Daly on her final run on said it was "for a great cause" and "whatever we could do to help, we jumped up to it"."It was emotional and I'm glad I had my sunglasses as we all got a little bit choked up because it was so beautiful and it's what it's all been about," Ms Winton. Andrew Gardham from MacMillan Jersey liaised with Ms Daly on her fundraising challenge for the cancer said: it was "absolutely fantastic to see Daisy finish off after all of her hard work", and that it was "really important for us to have fundraisers like Daisy".Mr Gardham added: "Not only has Daisy raised fantastic funds but also by sharing her story so bravely, it's been so impactful for other people to be diligent and to be careful in the sun." MacMillan Jersey advises that people stay in shade when the sun is at its strongest, cover up skin when UV rays are high and wear suncream on exposed skin to reduce the risks of getting skin cancer.
